Karyopharm Therapeutics

Global Secular Trends Will Drive Adoption Of Targeted Oncology Therapies

AnalystHighTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

13 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

US$66.25

88.7% undervalued

21 Aug

US$7.46

-37.8%

19.9%

-37.8%

19.9%

Author's Valuation

US$66.3

88.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$66.3

88.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

26.90%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.32%

Calculation

US$61.87m

Earnings '28

14.71x

PE Ratio '28

US$910.23m

Market Cap '28

US$910.23m

Market Cap '28

9.70m

No. shares '28

US$93.88

Share Price '28

US$93.88 Share Price '28

Discounted to 2025 @ 12.32% p.a.

US$66.25

Fair Value '25